The current RSP arrangement was never ONLY for RVX-208. It covered any compound that generated net Apo Revenue (aka modulated apoAI). So I agree, that this new amendment seems to be expanding the net, but just to clarify the original RSP arrangment was never ONLY for RVX-208.

"Net Apo Revenue is calculated, among other things, based on Apo Products and Apo Intellectual Property Rights, which are limited to products and intellectual property rights that fall within the field of the prevention, treatment or mitigation of any disease via the administration of a pharmaceutical agent that results in therapeutic relevant elevation in the plasma levels of Apolipoprotein A-1 (“ApoA-1”) that in a predictable model of ApoA-1 expression, using either a human or nonhuman primate model, the pharmaceutical agent is demonstrated to have at least a seven percent (7%) increase in humans and fifty percent (50%) increase in nonhuman primates in the ApoA-1 plasma level in two consecutive weeks of treatment using less than 30 milligrams – b.i.d. (60 milligrams per day) of the pharmaceutical agent per kilogram of the weight of the subject."

"The terms of the Royalty Preferred Shares currently entitle the holder of the Royalty Preferred Shares to a dividend calculated based on a percentage of net revenue earned by the Corporation from the sale or licensing of products or intellectual property rights that increase the plasma levels of ApoA-1, a component of the complex of lipids and proteins that are associated with a decreased risk of atherosclerosis and coronary heart disease.

As indicated above, detailed study of the results of the Corporation’s clinical trial program indicates that apabetalone/RVX-208 has been shown to affect expression of numerous targets important for cardiovascular disease and ApoA-1 is only one of these targets. Therefore, the Corporation has determined that it is necessary to amend the terms of the Royalty Preferred Shares to remove the requirement that the pharmaceutical agent elevate plasma levels of ApoA-1."